Hatasu Kobayashi, Yurie Mori, Sharif Ahmed, Yuichiro Hirao, Shinya Kato, Shosuke Kawanishi, Mariko Murata, Shinji Oikawa
Journal: The Journal of infectious diseases 2023;227(9):1068-1072
PMID: 36461940
Molnupiravir is an antiviral agent recently used for treating coronavirus disease 2019 (COVID-19). Here, we demonstrate that N4-hydroxycytidine (NHC), a molnupiravir metabolite, treated with cytidine deaminase (CDA) induced Cu(II)-mediated oxidative DNA damage in isolated DNA. A colorimetric assay revealed hydroxylamine generation from CDA-treated NHC. The site specificity of DNA damage also suggested involvement of hydroxylamine in the damage. Furthermore, Cu(I) and H2O2 play an important role in the DNA damage. We propose oxidative DNA damage via CDA-mediated metabolism as a possible mutagenic mechanism of NHC, highlighting the need for careful risk assessment of molnupiravir use in therapies for viral diseases, including COVID-19.
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Full Text Sources:
Medical:
Miscellaneous:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.